Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium

Core Insights - Caris Life Sciences announced the presentation of 19 studies on various breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025, showcasing its leadership in precision oncology and AI-driven research [1][2][3] Group 1: Research and Studies - The studies cover seven distinct breast cancer subtypes, including HR+/HER2–, HER2-positive, HER2-low/ultralow/null, triple-negative, invasive lobular carcinoma, male, and metastatic breast cancer [2] - Collaborating institutions include over 40 leading cancer centers, emphasizing the extensive network and collaborative efforts in advancing precision oncology [2][8] - Key presentations include a multimodal AI model for predicting breast cancer recurrence and a deep learning model for late distant recurrence risk in HR+ early breast cancer [6][11] Group 2: Company Overview and Technology - Caris Life Sciences is recognized as a pioneering company in precision medicine, utilizing advanced AI and machine learning to analyze complex molecular data [9][10] - The company integrates whole exome and whole transcriptome sequencing with immunohistochemistry (IHC) profiling to enhance understanding of therapeutic resistance and patient outcomes [3][9] - The Caris Precision Oncology Alliance consists of 98 cancer centers and institutions, focusing on optimizing standards of care for molecular testing and improving clinical outcomes for cancer patients [8]